• Target disease: Visceral leishmaniasis (VL)
  • Main partners (since project start): BRAZIL: Brasilia University; Hospital Sao José de Doencas Infecciosas; Leishmaniasis Control Programme/Ministry of Health; Montes Claros State University; Paediatric Hospital Joao Paulo II – FHEMIG; Piaui Federal University; Rene Rachou Research Center– Fiocruz-MG; Sergipe Federal University; Universidade Estadual do Rio de Janeiro.
  • Project start: February 2011
  • Funding (since project start): Associação Bem-Te-Vi Diversidade, Brazil; CNPq/FINEP; Department for International Development (DFID), UK; Médecins Sans Frontières/Doctors without Borders, International; Medicor Foundation, Liechtenstein; Ministry of Health, Brazil; Spanish Agency for International Development Cooperation (AECID), Spain; Swiss Agency for Development and Cooperation (SDC), Switzerland; Other private foundations and individuals.


Overall Objective:

  • Assess the efficacy and safety of amphotericin B deoxycholate, AmBisome® and AmBisome® combined with Glucantime®, as compared to the first-line treatment, Glucantime®, for the treatment of visceral leishmaniasis patients in Brazil, supporting the Brazilian Ministry of Health and its partners.


In 2011, a Phase IV study sponsored by the Brazilian Ministry of Health (FINEP) was initiated at five sites in Brazil to evaluate the efficacy and safety of Amphotericin B deoxycholate, AmBisome®, and a combination of AmBisome® and Glucantime®, in comparison to Glucantime®, the existing first-line treatment of visceral leishmaniasis. 378 patients were recruited. Brazil’s national guidelines for visceral leishmaniasis were revised in 2013 based on the interim safety data from the trial. While Glucantime® remains the first-line treatment, AmBisome® replaced Amphotericin B deoxycholate as a second-line treatment.


The Brazilian Ministry of Health is still reviewing its treatment policy to consider the adoption of AmBisome as the country’s first-line visceral leishmaniasis treatment.

The Brazilian Ministry of Health is reviewing its policy with regard to the adoption of AmBisome® as first-line treatment for visceral leishmaniasis.

The final results of this trial were presented to the Ministry of Health, and are expected to guide further policy change in Brazil as of 2017.

Last update: February 2019